MetaCap

Amarin Corporation plc (AMRN)

NASDAQ: AMRNHealth CareBiotechnology: Pharmaceutical PreparationsUSD

10.57-0.69 (-6.13%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

AMRN stock chart

Technical analysis

Key statistics

All statistics
Market cap
$444.39M
EPS (TTM)
-$0.80
52-week range
10.56 – 17.31
Day range
10.56 – 11.30
Volume / Avg
177.91K / 79.50K
Beta
—

52-week range

$10.56$17.31

AMRN stock today

Shares of Amarin (AMRN) finished lower on Nov 20 at $10.57, a drop of 6.13% or $0.69 per share, versus the S&P 500's 3.70% decline. Volume was 2.2x the average at 177.91K shares, a sign of unusually heavy trading. At this level, AMRN sits near the bottom of its 52-week range of $10.56 to $17.31: 38.9% below the high, set on Jan 23, 2026 and 0.1% above the low.

AMRN is down 24.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 35.5%. Amarin has posted a net loss over the last twelve months (EPS of -$0.80), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Amarin

Company profile

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally through wholesalers, selected regional wholesalers, and retail and mail order pharmacy providers.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Aaron D. Berg
Headquarters
Dublin
Employees
80

Financial highlights

Full financials

In fiscal 2025, Amarin generated $213.6 million in revenue, down 6.5% from fiscal 2024, its first annual decline since 2024. Amarin reported a net loss of $38.8 million, compared with a loss of $82.2 million a year earlier. Gross margin was 56.6% (up from 35.6%) and operating margin -23.5%.

Amarin annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$213.65M$228.61M$306.91M$369.19M$583.19M
Growth-6.55%-25.51%-16.87%-36.69%-5.03%
Net income$-38.80M$-82.18M$-59.11M$-105.80M$7.73M
EPS (diluted)$-0.09$-0.20$-0.15$-0.26$0.02

Analyst forecast

Forecast

Consensus (1 analysts)

none

Avg. price target

$13.00+22.99%

  • Strong buy 0
  • Buy 0
  • Hold 0
  • Sell 0
  • Strong sell 1

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 28, 2026
EPS actual vs est.
$0.00 vs $-0.28
Surprise
+100.00%

AMRN news

All AMRN news

Amarin peers

Health Care sector
AMRN peer companies
CompanyPrice% ChgMarket capCompare
DMACDiaMedica Therapeutics Inc.8.25+2.87%$445.15Mvs AMRN
CTMXCytomX Therapeutics Inc.2.03-0.98%$442.55Mvs AMRN
KMDAKamada Ltd.7.74-1.15%$446.85Mvs AMRN
LYELLyell Immunopharma Inc.13.80+1.62%$441.82Mvs AMRN
CAPRCapricor Therapeutics Inc.7.59+0.80%$441.30Mvs AMRN
AQSTAquestive Therapeutics Inc.3.46-6.61%$434.88Mvs AMRN
STTKShattuck Labs Inc.4.46-1.98%$454.22Mvs AMRN
ASMBAssembly Biosciences Inc.22.19-1.38%$454.39Mvs AMRN

Indexes, lists and sector

Amarin stock FAQ

What is Amarin's stock price today?

AMRN last traded at $10.57 as of Nov 20, 4:00 PM EST, down 6.13% on the day. Prices are delayed at least 15 minutes.

Does Amarin pay a dividend?

No. Amarin does not currently pay a regular cash dividend.

Who is Amarin's CEO?

Mr. Aaron D. Berg is the chief executive officer of Amarin Corporation plc, which has about 80 employees.

Has AMRN ever split its stock?

Yes. The most recent AMRN stock split was a 1-for-20 split on Apr 11, 2025, one of 3 splits on record.

What is the AMRN 52-week high?

The 52-week high for AMRN is $17.31 and the 52-week low is $10.56. The stock is currently 38.9% below its high.

Compare AMRN